



OncoMed Pharmaceuticals
Investor Relations Department
800 Chesapeake Drive
Redwood City, CA 94063
United States

[Visit IR website](#)
[Sign-up for email alerts](#)

NASDAQ: OMED ¹

Last Trade:	2.32
Trade Time:	4:00 PM ET Sep 21, 2018
Change:	-0.08 (3.333%)
Day Range	2.30 - 2.45
52-Week Range	1.74 - 5.56
Volume	233,075
Market Cap. (\$M)	89.320
Shares Out (M)	38.500

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. To date, we have advanced nine novel anti-cancer product candidates into more than 14 IND's, initiated 27 clinical studies and have enrolled more than 1,300 subjects. We continue to pursue the discovery of additional novel anti-cancer therapeutics. All of our product candi.....
[\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Sep 20, 2018*
[OncoMed Provides Update on Navicixizumab Partnership](#)
- Aug 29, 2018*
[OncoMed to Present at Two Upcoming Investor Conferences in September](#)
- Aug 2, 2018*
[OncoMed Announces Second Quarter 2018 Financial Results and Operational Highlights](#)
- Jun 12, 2018*
[OncoMed Doses First Patient in Phase 1b Portion of anti-TIGIT Clinical Trial](#)
- May 8, 2018*
[OncoMed Announces First Quarter 2018 Financial Results and Operational Highlights](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 9, 2018*
[Annual Report \(10-K\)](#)
- Apr 27, 2018*
[Definitive Proxy Statement](#)
- Aug 2, 2018*
[Quarterly Report \(10-Q\)](#)
- May 8, 2018*
[Quarterly Report \(10-Q\)](#)
- Nov 2, 2017*
[Quarterly Report \(10-Q\)](#)